Consistent with Actelion's second Strategic Principle “Retain the value of innovation“, Actelion considers sophisticated partnerships to strategically access technologies or products, and to maximize the value of our discovery engine and late-stage pipeline. In general, the purposes of our partnerships are to:
Being a global and a fully integrated biopharmaceutical company, Actelion can offer a credible and established platform to partners with innovative technologies or products, while providing benefits to both parties.
Actelion has a dedicated team focused on identifying innovation from external sources that complements our business approach.
Learn more about our collaborations with ReveraGen BioPharma, Inc., Nippon Shinyaku, Bayer Schering Pharma AG and Oxford GlycoScience.
Actelion mainly integrates additional innovation into its pipeline through in-licensing, but does not exclude acquisitions should the opportunity arise.
Learn more about Actelion's previous acquisitions: Axovan, CoTherix Inc., and Ceptaris Therapeutics Inc.
Vaxxilon AG is dedicated to the discovery, development and commercialization of innovative synthetic carbohydrate vaccines to prevent, first and foremost, bacterial infections. Vaxxilon has licensed multiple preclinical vaccine candidates to target pathogens for which there are no approved vaccines, or for which existing vaccines do not fully meet medical needs. Vaxxilon was created in 2015 by Actelion Ltd and the Max Planck Society. The company is based on the scientific insights and innovation of Professors Peter Seeberger of the Max Planck Institute of Colloids and Interfaces and Gennaro de Libero of the University Hospital of Basel.